Flowchart of participant screening, enrollment, withdrawal, and protocol completion Asterisk indicates those with partial or missing data included in analyses.

Slides:

Advertisements

Similar presentations

Derivation of analytic sample. ED indicates erectile dysfuntion; MEC, Mobile Examination Center Christopher S. Saigal, et al, Arch Intern Med. 2005;166:

Advertisements

Time line of data collection in the Nurses’ Health Study, 1988 to 2000 A. Heather Eliassen et al, Arch Intern Med. 2005; 165:

Enrollment and Outcomes J.J.P. Kastelein, et al. N Engl J Med 2008;358:1431.

The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.

Baseline Characteristics of Patients Referred for Stress Myocardial Perfusion Testing by Erectile Function Classification James K. Min, et al, Arch Intern.

Flowchart of study participants MedDiet indicates Mediterranean diet; VOO, virgin olive oil Jordi Salas-Salvado, et al. Arch Intern Med 2008;168:

Date of download: 6/2/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effectiveness of Foot Orthoses to Treat Plantar Fasciitis:

Date of download: 6/25/2016 Copyright © 2016 American Medical Association. All rights reserved. From: The Colorado Thyroid Disease Prevalence Study Arch.

(a) Respiration rates ±s. e

Baseline Mean Daily Servings of Coffee and Other Beverages and of Caffeine in Women in the Iowa Women’s Health Study, 1986* *Data are given as.

Flowchart of participants

Copyright © 2012 American Medical Association. All rights reserved.

Baseline Characteristics of the Patients Part I

Figure S2 A B Log2 Fold Change (+/- cAMP) Transcriptome (9hr)

Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.

Characteristics of the Folic Acid and Placebo Groups at the Start of the Study J. Durga et al. Arch Intern Med. 2005;165:

Copyright © 2002 American Medical Association. All rights reserved.

Treatment LDL-C: baseline (mg/dL) LDL-C: 24 mo (mg/dL) p

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

CHOICE: Relative risk of death on peritoneal dialysis vs hemodialysis

Effect of evolocumab on lipoprotein particles

PREMIER: Rate of hypertension at 18 months

Study Design Ketil Lunde, et al. N Engl J Med 2006;355:

Jun M, et al. Lancet 2010 Epub May 10

Fellström BC, et al. N Engl J Med 2009;360:1455-7

Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

Description of studies for pooled analyses

Fung TT, et al. Circulation 2009;119:

Measure Acute rejection Chronic allograft nephropathy

Line graph showing change in size over time relative to baseline CT

OSLER Trial design: Patients from five phase 2 trials and seven phase 3 trials with evolocumab were invited to participate in the OSLER extension program,

Fig. 1. MAHALO clinical trial flowchart.

Relative risk reduction for incident hypertension associated with weight loss of 6.8 kg: The Framingham Study Cohort Risk reduction (%) Relative risk.

Titration of antibiotic perturbations results in altered community structures and C. difficile colonization resistance. Titration of antibiotic perturbations.

Fig. 3 Liver stiffness and NT-proBNP concentration after treatment with miridesap followed by dezamizumab. Liver stiffness and NT-proBNP concentration.

NAFLD (nonalcoholic fatty liver disease), CVD, and type 2 diabetes: Details of the study design Targher G et al. Diabetes Care 2007;30:

Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%

Enrollment and Outcomes

Trichopoulou A, et al. BMJ 2009;338:b2337

Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.

Concentrations of (A) faecal IgA (µg IgA/µg TP), (B) serum IgA (g/l) and (c) serum IgE (g/l) in puppies at 7 weeks, 12–13 months and 15–18 months of age.

Heart Protection Study Collaborative Group Lancet 2011;377:469-76

Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:

Study Participant Flow

Baseline Characteristics of the Patients and Use of Concomitant Medications – Part I Kaare Harald Bønaa, et al. N Engl J Med 2006;354:

Baseline Characteristics of the Study Participants

Baseline Characteristics, Blood Pressures, and Laboratory Values

Trend of overall improvement in CKD risk categories after bariatric surgery using year 1 post-surgery as baseline. Trend of overall improvement in CKD.

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

Parathyroid hormone (PTH) levels by Dialysis Outcomes and Practice Patterns Study (DOPPS) phase and selected patient characteristics. Parathyroid hormone.

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

Characteristics of Participants in the Nurses Health Study According to Alcohol Intake Meir J.Stampfer et al N Engl J Med 2005;352:

Flowchart of Manuscript Selection

Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.

Baseline Characteristics of the Patients – Part I

Two way sensitivity analyses of the sensitivity and specificity of HSV-2 type specific ELISA. Each line represents a different estimate of ELISA specificity.

Baseline characteristics of the 1,842 men without coronary heart disease and the 230 men with a first coronary heart disease event during the 13-year.

Enrollment and Outcomes

Titration activities from baseline up to 6 and 12 months follow-up in nurse-coordinated care (NCC) versus usual care patients. X-as: patients (percentage),

Plasma Levels Correlate with Clinical Benefit

Fig. 3 Liver stiffness and NT-proBNP concentration after treatment with miridesap followed by dezamizumab. Liver stiffness and NT-proBNP concentration.

Flow of study participants

Average percent change in serum leptin and soluble leptin receptor (sOB-R) levels in response to rhLeptin administration at a low dose (0.01 mg/kg) (n.

Flowchart of the process of study selection LAR indicates laboratory-defined aspirin resistance Jaapjan D. Snoep, et al. Arch Intern Med 2007;167:

Proportions of subjects with ≥50% reductions in all qualifying regions of residual limb pain and phantom limb pain. Proportions of subjects with ≥50% reductions.

Doses of trial medication in the liraglutide groups (A) and in the placebo groups (B). Doses of trial medication in the liraglutide groups (A) and in the.

Tipifarnib combined with bortezomib induces cell death in diverse multiple myeloma and AML cell lines. Tipifarnib combined with bortezomib induces cell.

Changes of visual acuity (VA) at baseline, at 3 and 6 months before, and at 3, 6 and 12 months after the initiation of the administration of sodium–glucose.

Boxplots of diffusion (A and B) and perfusion (C) characteristics in brain metastases (gray), glioblastomas (white), and PCLs (dotted). Boxplots of diffusion.

Medication intensity (ALLP) changes between baseline and 6 months, by (not) being low-density lipoprotein-cholesterol (LDL-C) target at baseline for nurse-coordinated.

Presentation transcript:

Flowchart of participant screening, enrollment, withdrawal, and protocol completion Asterisk indicates those with partial or missing data included in analyses using the mixed procedure (PROC MIX, SAS 9.1 Service Pack 3; SAS Institute, Cary, NC) Christopher D. Gardner, et al. Arch Intern Med 2007;167:346-353

Baseline Characteristics* Christopher D. Gardner, et al. Arch Intern Med 2007;167:346-353

Lipid Results by Group and Time Point* Christopher D. Gardner, et al. Arch Intern Med 2007;167:346-353

Six-month percent change (mean and SE) relative to the end of the run-in phase in participants with available data Christopher D. Gardner, et al. Arch Intern Med 2007;167:346-353

Values in the Subset of Participants With LDL-C Concentrations Above the Median at the End of the Run-in Phase Who Completed the 6-Month Protocol* Christopher D. Gardner, et al. Arch Intern Med 2007;167:346-353